Berlin – Promising early results from a Phase I/II clinical trial of OPGx-BEST1 gene therapy are offering hope for individuals living with best vitelliform macular dystrophy (BVMD) and autosomal-recessive bestrophinopathy (ARB), two inherited retinal diseases that lead to progressive vision loss. Opus Genetics, the company developing the therapy, recently presented data at the 49th annual meeting of the Macula Society in San Diego, California, demonstrating both safety and early signs of improved vision in a participant with ARB.
BVMD and ARB are caused by mutations in the BEST1 gene, which provides instructions for making bestrophin-1, a protein crucial for the health and function of the retinal pigment epithelium (RPE). The RPE supports the photoreceptor cells responsible for vision. Mutations in BEST1 disrupt this support, leading to the accumulation of fluid and deposits under the retina, ultimately causing central vision loss. Currently, there are limited treatment options available for these debilitating conditions, making the development of OPGx-BEST1 a significant step forward.
Gene Therapy Shows Promise in Early Trials
The ongoing open-label, adaptive Phase I/II study is designed to assess the safety, tolerability, and potential efficacy of a single subretinal injection of OPGx-BEST1. The trial is enrolling adult participants diagnosed with either BVMD or ARB, dividing them into two dosing cohorts. Researchers are meticulously monitoring participants for both short-term and long-term outcomes, evaluating biological activity through a combination of functional and anatomical assessments. The initial data presented at the Macula Society meeting focused on a 63-year-old female participant with ARB.
After three months post-injection, OPGx-BEST1 demonstrated a favorable safety profile, with no reports of ocular inflammation, adverse events, or dose-limiting toxicities. This represents a critical finding, as safety is paramount in gene therapy trials. More encouragingly, the participant exhibited early signs of functional improvement. Specifically, her best-corrected visual acuity (BCVA) – a measure of sharpness of vision – improved by 12 letters on the standard eye chart. Central subfield thickness, an indicator of fluid accumulation in the macula, decreased by 23%, and intraretinal fluid resolved in areas with less atrophy within one month of treatment. As reported by Clinical Trials Arena, these initial findings suggest the potential for OPGx-BEST1 to halt or even reverse some of the vision loss associated with ARB.
Understanding the Mechanism of Action
OPGx-BEST1 utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the BEST1 gene directly to the RPE cells. AAVs are commonly used in gene therapy as they are relatively harmless and efficient at delivering genetic material. Once inside the RPE cells, the delivered gene instructs the cells to produce functional bestrophin-1 protein, restoring the critical support system for the photoreceptors. This approach aims to address the underlying genetic defect driving the disease, rather than simply managing the symptoms.
Recruitment and Future Outlook
Currently, recruitment for the Phase I/II trial is ongoing at two sites in the United States, with plans to expand to additional locations in Cincinnati, Florida, and New York. As of March 2026, two participants have been enrolled, and three-month results from the full Cohort 1 are anticipated in mid-2026. This will provide a more comprehensive assessment of the therapy’s safety and efficacy across a larger group of patients.
Opus Genetics CEO George Magrath expressed enthusiasm about the initial results, stating, “We are encouraged by these results from our sentinel participant, showing OPGx-BEST1 was well-tolerated and demonstrated promising initial efficacy at three months. Although early, this data represents an significant milestone for our OPGx-BEST1 programme and for patients with BEST1-related retinal diseases.” The company first dosed a subject in the trial in November 2025, marking a significant step in the development of this potentially transformative therapy.
The Importance of Gene Therapy for Inherited Retinal Diseases
Inherited retinal diseases, like BVMD and ARB, collectively affect millions of people worldwide. These conditions often lead to significant visual impairment and, in many cases, complete blindness. Gene therapy offers a potentially curative approach for these diseases by addressing the underlying genetic cause. While gene therapy is still a relatively new field, recent advances have demonstrated its potential to restore vision in patients with previously untreatable conditions. The success of OPGx-BEST1, if confirmed in larger trials, could pave the way for similar gene therapies targeting other inherited retinal diseases.
The development of OPGx-BEST1 represents a beacon of hope for individuals and families affected by BVMD and ARB. The early data presented at the Macula Society meeting are encouraging, and the ongoing Phase I/II trial will provide further insights into the safety and efficacy of this innovative gene therapy. As research continues and more therapies become available, the future looks brighter for those living with these challenging conditions.
The next key milestone will be the release of the three-month results from the full Cohort 1 in mid-2026. Continued monitoring of enrolled participants and expansion of the trial to additional sites will be crucial in determining the long-term potential of OPGx-BEST1. For those interested in learning more about the trial or participating, information can be found on the Opus Genetics website and through clinical trial registries.
Disclaimer: I am a medical journalist and this article is for informational purposes only. It’s not a substitute for professional medical advice. Always consult with a qualified healthcare provider for any questions you may have regarding a medical condition or treatment.